Boston Scientific (NYSE:BSX) said yesterday that it closed the $600 million acquisition of Augmenix and its SpaceOar device. The deal for Bedford, Mass.-based Augmenix, announced in September, called for $500 million in up-front cash and another $100 million pegged to sales-based milestones. “This close marks the third completed acquisition in 2018 for the company’s urology & […]
augmenix
Medtech M&A remains hot: Here’s how
M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig. The number of medtech M&A deals soared by 50% in 2017 and […]
What you should know about today’s top trends in medtech
Medtech’s hottest topics in M&A, intellectual property, finance and regulation will be on the agenda at DeviceTalks Boston Oct. 8-11. Patent attorney David Dykeman from the Boston office of the global law firm Greenberg Traurig will moderate the Oct. 9 hot topics panel in which the discussion will center around: · M&A trends from the perspective of […]
